DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

GlaxoSmithKline (NYSE: GSK)

44.37 -0.42 (-0.94%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GSK $44.37 -0.94%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $44.68
Previous Close $44.79
Daily Range $44.26 - $44.69
52-Week Range $41.25 - $54.78
Market Cap $107.2B
P/E Ratio 15.39
Dividend (Yield) $2.31 (5.6%)
Ex-Dividend Date
Dividend Pay Date
05/13/15
07/09/15
Volume 3,235,629
Average Daily Volume 3,907,402
Current FY EPS $2.52

Sector

Healthcare

Industry

Drug Makers

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

News & Commentary Rss Feed

Is This Pfizer's Next Move?

Analysts at Deutsche Bank recently suggested that Pfizer may have interest in buying GlaxoSmithKline. While the two companies have several shared areas of interest, this megamerger is far from a perfect fit. Here's why.

Veeva Beats Q1 Earnings on Strong Revenues, Stock Down - Analyst Blog

3 Stocks With an Unsustainable Dividend Payout Ratio

Dividends are what often separate the good from the great retirement portfolios, but they can also pack hidden danger. Find out how you can use the dividend payout ratio to help locate these "dangerous" stocks.

Veeva's Earnings Growth Leaves Investors Unimpressed

The life-sciences-focused cloud-computing company once again posted solid growth in sales and profits, but investors wanted more.

Did BioMarin Bet on the Wrong Experimental DMD Drug?

Sarepta Therapeutics may hold a key advantage over BioMarin in the race to bring a game-changing Duchenne muscular dystrophy drug to market. Here's why.

Why Dividend Investors Should Love These 5% Yielding European Stocks

Big Pharma Companies Are Betting On Regenerative Medicine - Should You?

Sector Leaders See 5.9% Advantage For 5 Highest-Yield, Lowest-Priced May Dividend Dogs

Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

9 International Dividend Dogs With Upside Potential

See More GSK News...

GSK's Top Competitors

GSK $44.37 (-0.94%)
Current stock: GSK
PFE $34.75 (0.90%)
Current stock: PFE
JNJ $100.14 (-1.00%)
Current stock: JNJ
RHHBY $38.46 (2.83%)
Current stock: RHHBY